Blog

The battle for immortality - a $ 600 billion industry

One of the biggest investment opportunities in the next decade will be the companies that work to postpone human death.

This market is expected to reach $ 600 billion by 2025, one of the largest investment banks in the United States predicts.

Bank of America analysts Merrill Lynch Felix Tran and Haim Israel believe that genome sequencers such as Illumina, high-tech players such as Alphabet and biotech companies such as Novartis are on the cusp of “bringing unprecedented increases to the quality and length of human lifespans.” CNBC reports.

According to analysts, innovations in genomic science, data transfer and "immortality" could soon lead to the fact that human life will last much longer than 100 years.

Medical knowledge will double every 73 days by 2020 vs. every 3.5 (years) in 2010, and genomic sequencing costs have fallen 99.999% since 2003,, Israel and Tran still indicate.

According to them, all this creates new expectations for medicine to extend human life on the basis of the technological revolution, or in other words - heralding a ‘techmanity’ (technology meets humanity) revolution.

The extension of human life - a favorite topic of science fiction novels - is beginning to become a competitive method of making money in capital markets.

The Bank of America highlights five key sub-themes, with potential in this industry, reaching $ 110 billion - genomics, big data/AI health, future food, “ammortality” and “moonshot medicine” — as well as several stocks that offer exposure to the trend.

Genomics

Genomics, or the study of the human genome, is expected to be a $41 billion industry by 2025 and will provide the “next generation of gene editing technology offering potentially revolutionary advances in prevention and disease treatments,” Bank of America said.

Companies such as $46 billion genome sequencer Illumina, $27 billion lab instrument manufacturer Agilent and $89 billion life science equipment maker Danaher all have exposure to the space.

In particular Illumina plays “an important role in helping advance disease research, drug development, and the creation of molecular tests, Tran and Israel add.

Data/Artificial intelligence

The growth of artificial intelligence combined with an ever-growing body of health-care data should help the researchers, in the years, to analyze pathology, or the causes and effects of the diseases.

Improvements in the technology have the potential to bring down health-related costs and enable precision medicine, the analysts consider.

Names in this space, which is expected to grow to $36 billion by 2025, include Alphabet, Amazon and Apple.

Future food

Prospective food companies of the future are expected to ensure “healthier eating and sustainable humanity on the planet,”

According to the Bank of America analyzers, these companies, should leverage agricultural gene editing, which will lead to healthier lifestyles and consumption.

Ammortality

The “ammortality” theme is expected to be worth $504 billion by 2025. Innovation should lead to an extension of human life and elimination of disease.

Companies that play a large role in this niche are Intuitive Surgical and Zimmer, which worked with Apple Watch to conduct a clinical study for 10,000 knee and hip replacement patients.

Moonshot medicine

The companies in this area, whose name is a metaphor for advanced medicine and medical procedures, include the well-known Illuminas, as well as other genomics companies and therapy makers such as Sangamo, Vertex Pharma and Neurocrine.

These companies are working on cures or treatments for some of humanity’s toughest diseases, ranging from cystic fibrosis to Parkinson’s and Alzheimer’s.

Leave a comment